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Abstract
The heptapeptide angiotensin-(1–7) (Ang-(1–7)) is protective in the cardiovascular system
through its induction of vasodilator production and angiogenesis. Despite acting antagonisti-
cally to the effects of elevated, pathophysiological levels of angiotensin II (AngII), recent evi-
dence has identified convergent and beneficial effects of low levels of both Ang-(1–7) and
AngII. Previous work identified the AngII receptor type I (AT1R) as a component of the pro-
tein complex formed when Ang-(1–7) binds its receptor, Mas1. Importantly, pharmacological
blockade of AT1R did not alter the effects of Ang-(1–7). Here, we use a novel mutation of
AT1RA in the Dahl salt-sensitive (SS) rat to test the hypothesis that interaction between
Mas1 and AT1R contributes to proangiogenic Ang-(1–7) signaling. In a model of hind limb
angiogenesis induced by electrical stimulation, we find that the restoration of skeletal mus-
cle angiogenesis in SS rats by Ang-(1–7) infusion is impaired in AT1RA knockout rats.
Enhancement of endothelial cell (EC) tube formation capacity by Ang-(1–7) is similarly
blunted in AT1RA mutant ECs. Transcriptional changes elicited by Ang-(1–7) in SS rat ECs
are altered in AT1RA mutant ECs, and tandem mass spectrometry-based proteomics dem-
onstrate that the protein complex formed upon binding of Ang-(1–7) to Mas1 is altered in
AT1RA mutant ECs. Together, these data support the hypothesis that interaction between
AT1R and Mas1 contributes to proangiogenic Ang-(1–7) signaling.
Introduction
Microvascular dysfunction is an important risk factor for highly prevalent cardiovascular dis-
eases including hypertension and diabetes. The renin-angiotensin system (RAS) plays a key
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role in maintaining microvascular function. Systemic manipulation of the RAS, especially by
interfering with the signaling of angiotensin II (AngII) at the angiotensin II receptor type 1
(AT1R), is now a mainstay of treatment in cardiovascular disease. The success of drug treat-
ments targeting the RAS has suggested that signaling via AT1R is predominantly associated
with negative health outcomes. However, recent studies reaffirm that AngII/AT1R signaling
plays a key role in vascular homeostasis. For instance, renin suppression in animal models
impairs angiogenesis [1] and vascular reactivity to vasodilator stimuli[2], and restoration of
physiological AngII levels in models of impaired renin regulation restores vascular reactivity
and endothelial function [3,4].
While AngII is the canonical effector peptide of the RAS, other RAS peptides have become
increasingly interesting as avenues for therapeutic intervention. Foremost among these is
angiotensin-(1–7) (Ang-(1–7)), a RAS effector peptide with effects mediated by the receptor
Mas1 [5].
Ang-(1–7) has been shown to exhibit several protective cardiovascular effects that act antag-
onistically to pathophysiological elevations in AngII levels. These effects are wide-ranging,
including rescue of endothelial dysfunction and promotion of antifibrotic/antihypertrophic
phenotypes [6,7]. Conversely, under conditions of RAS suppression (i.e. low-renin hyperten-
sion or salt-induced renin-suppression) restoration of physiological AngII levels and low-dose
Ang-(1–7) have convergent, beneficial effects such as improvement of endothelial function
and rescue of impaired vasodilator responses[3].
The Ang-(1–7)/Mas axis of the RAS is relatively understudied, especially compared to the
AngII/AT1R axis, but recent studies have identified several key mediators of Ang-(1–7)/Mas
signaling. Several of these pathways are also important in AngII/AT1R signaling. For instance,
Ang-(1–7) contributes to endothelial homeostasis via ERK1/2, eNOS, PI3-kinase and Akt, all
of which are also associated with AngII signaling via AT1R [4,8–10]. A few relatively detailed
proteomic analyses of Ang-(1–7)/Mas signaling have been performed in our laboratory and by
others, and the results of those studies further support a convergence in AngII/AT1R and
Ang-(1–7)/Mas signaling [3,11].
In a previous effort to define proteins important to the transduction of Ang-(1–7)/Mas sig-
naling, we identified AT1R as a component of the protein complex formed when Ang-(1–7)
binds to its receptor, Mas1[3]. Heterodimerization of these receptors has been suggested previ-
ously. In fact, co-localization of AT1R and the receptor Mas1 has been demonstrated by biolu-
minescence energy transfer (BRET)[12], although dependence of Ang-(1–7)/Mas signaling on
the AT1R has yet to be described[12,13]. Here, we test the hypothesis that AT1R contributes to
the proangiogenic effects of Mas1 mediated Ang-(1–7) signaling. It is important to note that
pharmacological blockade of AT1R via losartan does not alter the effects of Ang-(1–7) treat-
ment[3]. Thus, the contribution of AT1R to Ang-(1–7)/Mas1 signaling in this model is inde-
pendent of AT1R ligand binding.
We have established an animal model of skeletal muscle angiogenesis in which one hind
limb is electrically stimulated to produce rhythmic muscular contractions over the course of
seven days, resulting in increased microvessel density in angiogenically competent rats[14]. In
this model, we have observed that modulation of the renin-angiotensin system affects angio-
genesis. In particular, suppression of the renin-angiotensin system genetically[1,15], pharma-
cologically[3,15,16], or via environmental factors[1] impairs angiogenesis. We recently
observed that low doses of angiotensin II and angiotensin-(1–7) have convergent, proangio-
genic effects in this model of impaired angiogenesis [3].
In this study, we investigate the restoration of normal microvascular function in the Dahl
salt-sensitive rat, a genetic model of low renin-angiotensin system activity and impaired angio-
genesis, to test the hypothesis that proangiogenic Ang-(1–7) signaling is dependent on the
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presence of AT1R. Using wild type Dahl salt-sensitive (SS-AT1WT) rats and Dahl salt-sensi-
tive rats with a novel mutation in AT1R resulting in an early truncation and loss of function
(SS-AT1KO), we assess the consistency of Ang-(1–7) induced effects at the physiological level
using a hind-limb model of angiogenesis, at the cellular level via endothelial cell tube forma-
tion, and at the molecular level via qPCR and tandem mass spectrometry-based proteomics.
Methods
Summary
Angiogenesis was assessed in catheterized, infused rats (3.0ng/kg/min Ang-(1–7) in 0.9%
saline) implanted with an electrical stimulator to induce unilateral, rhythmic contractions of
muscles in one hind limb[3]. The difference in vessel density between stimulated and unstimu-
lated limbs was used as a measure of angiogenesis. Angiogenic capability of endothelial cells
was assessed using an in vitro tube formation assay[17]. Total length of tubes was measured
using Pipeline software[18]. Gene expression was assessed by quantitative polymerase chain
reaction (qPCR). Mass spectrometry based proteomics was performed to capture interacting
proteins as previously described [3]. Briefly, endothelial cells were frozen in liquid nitrogen
and ground into a powder. This was followed by immunoprecipitation using Mas1 antibody
coupled magnetic beads, and captured proteins were subjected to liquid chromatography and
tandem mass spectrometry[3].
While humans express one AT1R protein, rats and mice express two versions of the protein,
angiotensin II receptor type 1a (AT1R A) and type 1b (AT1R B). In the rat, AT1R B is expressed
in the adrenal, but not the microvasculature [19]; thus we used a novel AT1R A knockout on
the background of the Dahl salt-sensitive rat along with its wild type control for these studies.
Functional deletion of the AT1R response in these animals was confirmed in vivo via an acute
blood pressure response to angiotensin II (0.32ug/kg i.v.).
Animals and infusion of angiotensin peptides
All animal protocols were approved by the Medical College of Wisconsin (MCW) Institutional
Animal Care and Use Committee. Animals were housed and cared for at the MCW Animal
Resource Center. All rats were maintained on normal salt diet (0.4% sodium chloride—AIN-
76A, Dyets Inc. #113755) for the duration of this study with free access to water, as previously
described [2]. Wild type, male Dahl salt-sensitive rats (SS-AT1WT) and male Dahl salt-sensi-
tive rats with a novel mutation in AT1R resulting in an early truncation and loss of function
(SS-AT1KO) underwent 7 days of hind-limb electrical stimulation and received different treat-
ments during the entire stimulation protocol. Rats were randomly assigned to the following
groups: vehicle infusion and Ang-(1–7) (2.6 ng � kg-1 �min-1 i.v.). All rats completed experi-
mental protocols at 9–12 weeks of age. Ang-(1–7) dosage was matched to previous studies in
this model[3]. That dose was chosen to be equimolar to a subpressor dose of AngII used in pre-
vious studies. Using reported in vivo half-lives of these peptides in rat models[20] and a simple
one-compartment model for the circulatory system, estimated plasma steady-state Ang-(1–7)
concentration was similar to baseline Ang-(1–7) concentrations reported in age-matched,
untreated Sprague-Dawley rats.
Zinc-Finger Nuclease (ZFN) mutant generation, and genotyping
For the AT1R A receptor knockout rats, ZFN constructs targeting the sequence
CTTTGCCCCTGTGGGCAGTCTATACCGCTATGGAGTACCGCT of exon 3 of the Agtr1A gene
were produced by Sigma-Aldrich (St. Louis, MO), where the underlined sequences indicate
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individual ZFN monomer binding on opposite strands. Messenger RNA encoding the Agtr1a
ZFN sequences was injected at a concentration of 10 ng/μl into the 1-cell pronucleus of SS/
JrHsdMcwi (SS) rat embryos and implanted into pseudopregnant females[21]. DNA was
extracted from founder generation pups at 10 days of age and used for PCR genotyping.
Founder mutants were identified by CEL-I assay and confirmed by Sanger sequencing [22]
using the following primers: forward, 5’-CCTCTACAGCATCATCTTTGTGG-3’; and
reverse, 5’-CACACTGGCGTAGAGGTTGA-3’. This process produced a 2-bp frame shift dele-
tion of bases (see below) in the ZFN target sequence, corresponding to nucleotides 521–522
(TC) of reference sequence NM_030985, and resulting in 12 nonsense amino acids before the
introduction of a premature stop codon. The mutant founder animal was bred to the parental
strain to establish germline transmission and a colony of SS-Agtr1aem1Mcwi mutant rats (RGD
ID: 5685369) was established.
Verification of mutation by restriction digest
Verification of the mutation in the AT1R A receptor protein itself was not possible by Western
blot analysis because commercially available antibodies are unable to specifically distinguish
between AT1R A and AT1R B receptor subtypes[23]. Therefore, RT-PCR of Agtr1a cDNA fol-
lowed by a restriction digest was performed. Based on Sanger sequencing results, the 2-bp
deletion creates a restriction site for the enzyme AccI (GTCTATACmutated to GTATAC) in the
knockout animals, which is not present in the SS parental strain.
SS rats and Agtr1a homozygous knockouts were maintained on a low salt (LS; 0.4% NaCl)
diet post-weaning and were sacrificed using Beuthanasia diluted in saline (final dose 195 mg/
kg pentobarbital sodium and 25 mg/kg phenytoin sodium). Tissue was obtained from the kid-
neys of each animal and stored in RNA Later (Life Technologies, Grand Island, NY). Total
RNA was extracted from a 25 mg tissue sample (IBI Scientific, Peosta, IA), and a volume of
RNA equal to 800 ng was reverse transcribed to cDNA using an AffinityScript cDNA Synthesis
Kit from Agilent Technologies (Santa Clara, CA) according to manufacturer’s instructions.
RT-PCR was performed with a Stratagene Mx3000P qPCR machine (Agilent Technologies,
Santa Clara, CA) using the cDNA product as a template run. Each 25 μl reaction contained
1.0 μl cDNA, 0.5 μl forward primer (10 μM), 0.5 μL reverse primer (10 μM), 12.5 μL RT2 SYBR
Green qPCR Mastermix, and 10.5 μL RNase-free water. The RT2 SYBR Green qPCR Master-
mix was obtained from Qiagen (Valencia, CA). AT1RA primers were: forward, 5’-GGAAA-
CAGCTTGGTGGTGAT-3’; and reverse, 5’-ACATAGGTGATTGCCGAAGG-3’. The thermal
profile was 95˚C denaturation for 10 minutes, followed by 40 cycles of 95˚C for 15 seconds
and 60˚C for 60 seconds.
The AccI restriction digest to differentiate between Agtr1a wild type and knockout animals
was performed as follows: each 50 μL reaction was composed of 1 μL AccI enzyme (New
England Biolabs, Ipswich, MA), 5 μL 10X NEBuffer 4, 15 μL RT-PCR product, and 29 μL
ddH2O. The reactions were digested at 37˚C for 90 minutes. In these studies, the wild type
AT1RA and AT1RB receptors should show a single band at 171 bp in the presence of Accl,
while the AT1RA knockout samples would show the 171 bp band for the AT1RB receptor and
two smaller bands (125 bp and 44 bp) for the AT1RA receptor because of the Accl restriction
site introduced by the mutation. The digest product or undigested control samples lacking the
Accl enzyme were run on a Tris-HCl Criterion Precast 15% polyacrylamide gel (Bio-Rad, Her-
cules, CA) at 240V for 45 minutes. The gel was post-stained with ethidium bromide before
being imaged with UV light.
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Anesthetized blood pressure recording
A Tygon catheter was implanted in the carotid artery of anesthetized (0.8L/min isoflurane)
SS-AT1WT and SS-AT1KO rats. Blood pressure was measured in the carotid artery using a
SPR-838 Millar Mikro Tip catheter (Millar Instruments). Blood pressure analysis was com-
pleted with WINDAQ software (DATAQ Instruments). A 100uL bolus of saline and/or a
100uL bolus of saline containing 0.32μg/kg AngII was administered via tail vein injection.
rt-PCR analysis of EC receptor expression
Endothelial cells were lysed with TRIzol (Invitrogen, 1 mL per 100mm plate). RNA was iso-
lated as previously described[24]. Purified RNA from sample was quantified with Nanodrop
spectrophotometer (Thermo Scientific) and run on a QuantStudio 6 Flex real-time PCR
machine (Applied Biosystems). Samples were run with the Taqman Fast Virus 1-step kit
(Applied Biosystems) per manufacturer’s instructions. The following gene expression assays
were used: Mas1 (Invitrogen 444889), AGTR1A (IDT Rn.PT.56a.18540744), and AGTR1B
(IDT Rn.PT.56a.37062306)
Immunoblotting
SS-AT1WT and SS-AT1KO rat cardiac microvascular endothelial cells (RMVECs) (Cell Bio-
logics) grown according to company protocol were brought to 70–90% confluency. Media was
aspirated and cells were scraped in MPER buffer (Pierce 78501) containing Protease Inhibitor
(Roche 11697498001. Cells were lysed with a 21-gauge needle and assayed for protein concen-
tration with MicroBCA kit (Pierce 23235). Thirty-five micrograms of protein from each sam-
ple was loaded on a 10% TGX PAGE gel (Biorad) and transferred to nitrocellulose. Blot was
blocked overnight in 5% NFDM (Biorad 1706404) and 1% BSA (Sigma A7906). Blot was incu-
bated with Mas1 primary antibody (Santa Cruz sc-135063) at 1:1000 dilution overnight at 4
degrees C. Blot was rinsed and incubated with goat anti-rabbit HRP-conjugated secondary
antibody (Biorad 1706515) at 1:5000 dilution for 1 hour. Blot was visualized with SuperSignal
West Pico Chemiluminescence Substrate (Pierce 34080). Membrane was imaged on Image-
Quant LAS 500 (GE Healthcare Life Sciences) and images were analyzed using ImageJ soft-
ware (https://imagej.nih.gov/ij/).
Electrical stimulator surgical procedures
Electrical stimulator and jugular catheters were implanted as previously described[25]. Anes-
thetized rats received subcutaneous incisions over the thoracolumbar region and medial aspect
of the right leg, and a miniature battery powered stimulator was implanted as previously
described[14]. Incisions were also made in the ventral and dorsal thoracic regions. A Tygon
catheter was implanted in the jugular vein, tunneled subcutaneously, and exteriorized at the
back of the neck. The catheter was passed through metal spring to a swivel allowing the animal
full range of motion. After 24 h of recovery, continuous infusion of Ang-(1–7) or saline vehicle
was started at a rate of 0.12 ml/h as noted above. The stimulator was activated by magnetic
reed switch and electrodes located near the common peroneal nerve in the lower leg produced
square-wave impulses of 0.3 ms duration, 10-Hz frequency and 3-V potential, causing inter-
mittent contractions of the tibialis anterior (TA) muscles for eight consecutive hours, daily for
the remainder of the study. The contralateral leg was used as a control and all animals were
euthanized after seven days of stimulation, followed by collection of the TA for morphological
analysis.
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Tissue harvest and morphological analysis of vessel density
Animals were euthanized by an overdose of Beuthanasia solution, and the stimulated and con-
tralateral unstimulated TA muscles were excised and weighed. Muscles were fixed overnight in
a 0.25% formalin solution, microsectioned, and immersed in a solution of 30μg/mL rhodamine
labeled Griffonia simplicifolia I (GS-I) lectin (Vector Labs) for 2 hours. The sections were
rinsed, mounted on microscope slides, and visualized with a fluorescent microscope system
(Nikon E-80i microscope with Q-Imaging QIClick camera, 200x)[14,25]. Images were taken
from at least twenty representative fields from each muscle and analyzed using Metamorph
software (Molecular Devices) for percent change in microvessel density[14,25]. Vessel counts
from all fields were averaged to a single vessel density defined as the mean number of vessel-
grid intersections per microscope field (0.155 mm2) for each muscle. Within experimental
groups mean vessel densities of stimulated muscles were compared to contralateral unstimu-
lated muscles, presented as mean ± SE, and evaluated using a paired t-test.
Angiogenesis tube formation assay
Tube formation assay was performed as in previous studies[3], with the exception of the slide
format used. SS-AT1WT and SS-AT1KO rat cardiac microvascular endothelial cells (RMVECs)
(Cell Biologics) grown according to company protocol were brought to 70–90% confluency,
washed twice with DPBS, and lifted using Enzymatic Free Cell Dissociation Buffer (Millipore)
with gentle agitation for 30 minutes at 37˚C. RMVECs were then centrifuged at 300 x g for 5
minutes, washed twice with DPBS, resuspended in 1 mL MCDB131 basal media plus 2% FBS,
and counted using the cell Countess system (Invitrogen). RMVECs were diluted for the addi-
tion of 1,250 cells in 50uL of media per well of u-Angiogenesis slides (iBidi) coated in 11 uL of
Geltrex (Thermo Fisher). Serum-starved and growth factor depleted conditions were utilized
as a tool to stunt normal RMVEC tube formation stimulation to better decipher changes that
would be observed through the addition of 100 nM Ang-(1–7). Treatment conditions included
RMVECs plus vehicle and RMVECs plus 100 nM Ang-(1–7). At 24 and 48 hours 10X magnifi-
cation images were taken using a TS100 Inverted Microscope (Nikon Corporation) for analysis
of the mean tube length per field (μm) using open-access PipeLine tube formation analysis
software[18]. The results were averaged across biological and technical replicates followed by
1-way ANOVA.
Isolation of Mas1 receptor signal protein complex
Immunoprecipitation was performed as in the previous study[3]. Previously, Mas1 immuno-
precipitation conditions without dithiobis(succinimidyl propionate) (DSP) crosslinker were
determined to be optimal due to DSP epitope inhibition[3]; therefore cryolysis was used in
place of crosslinking during the immuoprecipitations (IP) to stabilize the protein complex.
RMVECs were divided into 100 nM Ang-(1–7) treated (30 minutes at 37˚C) or non-treated
groups, washed 3 times with ice cold DPBS (non-treated) or DPBS plus 100 nM Ang-(1–7)
(treated), cells were scraped, and supernatants were transferred to 50 mL conical tubes. Fol-
lowing centrifugation at 300 x g for 10 minutes at 4˚C, supernatant was aspirated, washed with
10 mL ice cold DPBS plus or minus Ang-(1–7) as before, and the process was repeated twice.
RMVECs were resuspended in 20 mM Hepes/1.2% PVP buffer with protease inhibitors and
kept on ice until the next step. Cryolysis of the RMVECs was then performed in liquid nitro-
gen according to the Life Technologies cryolysis protocol in the Dynabeads Co-IP Kit (cat.
#143.21D). Frozen cell pellets were placed in a liquid nitrogen cooled 2 mL microcentrifuge
tube with a sterile metal bead, frozen tubes were secured in an oscillating homogenizer, and
samples were oscillated at 30 hertz for 1 minute three times or until a powder is formed; tubes
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were re-submerged in liquid nitrogen between each oscillation. Frozen cell pellet powders
were then resuspended in solution with anti-Mas1antibody (Santa Cruz; cat. #sc-135063) cou-
pled Dynabeads, incubated 30 minutes at 4˚C in a thermomixer at 500 rpm, and immuno-pre-
cipitated according to the Invitrogen Dynabeads Co-Immunoprecipitation Kit (cat. #143.21D)
and M-270 Epoxy Dynabeads Antibody Coupling Kit (cat. #143.11D) manufacturer protocols.
Liquid chromatography and mass spectrometry (ms) analysis
Liquid chromatography and mass spectrometry analysis was performed as in the previous
study[3]. Isolated protein samples were dried using a vacuum centrifuge, resuspended in
100 μL 25 mM ammonium bicarbonate, and prepared for LC-MS/MS as described previously
[26]. Tryptic peptide mixtures (1.9 μl) were separated using a NanoAccuity UPLC system
(Waters, Milford, MA) coupled with an in-house packed 5Å C18 resin (Phenomenex, Tor-
rance, CA) column (15 cm long 50μm inner diameter). A 120 minute gradient from 98%
HPLC water/2% ACN/0.1% formic acid to 98% ACN/2% HPLC water/0.1% formic acid was
used and peptides were analyzed using an LTQ-Orbitrap Velos MS(Thermo Scientific, Wal-
tham, MA). All Orbitrap Velos MS/MS settings utilized were as indicated in our previous stud-
ies[26,27]. Raw mass spectra were searched against a Uniprot Rodent Database in both
SEQUEST and MASCOT search algorithms, from which the best match for each scan was
kept after combining searches for individual runs. Variable modification of +57-Da for alkyl-
ation of cysteine and +16-Da for oxidation of methionine were included in search parameters.
Utilizing in-house Visualize proteomic analysis software[28], protein matches were filtered to
remove redundancies, to remove common contaminants, selected for a P�0.95 (FDR<5%),
and a comparison of groups was then run on the Ang-(1–7) treated versus non-treated
immuno-precipitation protein data. Further filters were applied to the comparison, including
significant increase in the Ang-(1–7) treated sample (p�0.05), presence in� 4 (of 6) runs
within a single biological group, and a fold change of at least 2 in the treated group compared
to the untreated group. This dataset was used for subsequent pathway mapping using a combi-
nation of UniprotKB, StringDB, Ingenuity Pathway Analysis, and Protein Center platforms.
Statistical analysis of MS/MS comparisons
All MS/MS statistical analyses were performed utilizing open source Visualize software with
built-in statistical analysis for large proteomic dataset comparison[28]. These analyses utilized
the G test, which is a log-likelihood ratio test, whose distribution can be approximated by a
chi-squared distribution with a single degree of freedom[29]. For null hypotheses we assume
that the expected proportion of scans for a given protein is directly related to the ratio of the
total scans in each group. Each observed scan count for each protein is multiplied by this ratio,
or its inverse depending on which group, to give us our expected frequency. Observed scans
from Group 0 (S0) are multiplied by the ratio of total scans in Group 1 (T1) over Total Scans
in Group 0 (T0) (E0 = S0�T1/T0), likewise observed scans from Group 1 (S1) are multiplied by
the ratio of T0 over T1 (E1 = S1�(T0/T1)). The specific G value calculation is 2 � (S0 � ln(S0/
E0) + S1 � ln(S1/E1)), and thus if our observed frequencies perfectly fit our expected frequen-
cies, we would get a G-value of 0, and a larger G-value the more our observed frequency depart
from our expected frequency. The distribution of G can be approximated by a chi-squared dis-
tribution with a degree of freedom of one to determine significance (P< 0.05), as described
previously[30].
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Real-Time PCR analysis of RMVECs
The RT2 ProfilerTM PCR Array PARN-024Z (QIAGEN) designed for profiling the expression
of 84 common angiogenesis related genes was used to examine expression changes induced in
RMVECs by Ang-(1–7). Comparisons were made between Ang-(1–7) stimulated and non-
stimulated RMVECs. One 100 mm plate of RMVECs was incubated plus/minus 100 nM Ang-
(1–7) in DPBS for 2 hours at 37˚C, scraped, and RNA was isolated using the RNeasy Mini-Kit
(QIAGEN, cat. #74104) according to manufacturer protocol. The RNase-Free DNase Set
(QIAGEN, cat. # 79254) was used for elimination of DNA contamination. Isolated RNA con-
centration was measured using absorbance on the NanoDrop System. ~400–700 ng of RNA
was then converted to cDNA using the RT2 First Strand Kit (QIAGEN, cat. # 330401) and
diluted according the manufacturer protocol for the RT2 ProfilerTM PCR Array PARN-024Z
(QIAGEN). RT2 SYBR Green ROXTM (QIAGEN, cat. # 330522) was used for the array. Sam-
ples were run in the QuantStudio 6 Flex (Applied Biosystems), thresholded and normalized
according to manufacturer protocol, and statistically analyzed using the QIAGEN online RT2
Profiler PCR Array Data Analysis Software version 3.5. RT-PCR analyses were then compared
with the proteomic pathway analysis data to formulate the influence of Ang-(1–7) on signaling
in RMVECs. Gene and protein lists were then analyzed using a combination of Ingenuity
Pathways Analysis software, UniprotKB, and Protein Center software to develop pathways
incorporating the data. Pathway figures were produced using Servier Medical Art (www.
servier.com).
Statistics and data analysis
Vessel density is presented as mean +/- standard error and was analyzed in SigmaPlot via
paired Student t-test. Tube formation data are presented as mean +/- standard deviation and
were analyzed in SigmaPlot via 1-way ANOVA with Dunnett’s Method for multiple compari-
sons. qPCR data is presented as mean +/- standard deviation and analyzed in SigmaPlot via
Student t-test. Gene expression array data was assessed via Deming regression and Student t-
tests with samples paired within the same plate, performed in SigmaPlot; p-values were then
assessed via a modified Hochberg’s step-up procedure[31] with false discovery rate set at 0.05.
Tandem mass spectrometry spectral data was analyzed using MASCOT, SEQUEST, and
VIZUALIZE, with differences identified via G-test as previously described[3].
Results
Molecular verification of selective mutation of the AT1RA receptor
Fig 1 shows a polyacrylamide gel performed to verify successful mutation of the AT1RA recep-
tor utilizing the AccI restriction digest. Total RNA was extracted from kidney samples taken
from SS rats and homozygous AT1RA receptor mutant rats and reverse transcribed to cDNA.
The cDNA was amplified with PCR using primers that did not differentiate the AT1R receptor
subtypes, and then subjected to AccI restriction digest. Expected full-length PCR products of
171 bp for the AT1RA and AT1RB receptors were present in the SS samples. However, AT1RA
samples subjected to Accl restriction digest showed 3 separate bands: a wild type AT1RB frag-
ment at 171 bp and bands at 125 and 44 bp representing the expected sizes of the digested
AT1RA mutant allele. In undigested cDNA control samples without Accl, the smaller bands
present in AccI restriction digests of cDNA from the AT1RA knockout animals were absent in
samples that were not exposed to the restriction enzyme.
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Physiological verification of selective mutation of the AT1RA receptor
Fig 2A and 2B shows acute blood pressure response to a bolus dose of AngII. Rats anesthetized
with pentobarbital were catheterized and baseline blood pressure was established. A 100uL
bolus of saline containing 0.32μg/kg AngII was administered via tail vein injection. A 100uL
bolus of saline alone produced no response. SS-AT1WT rats demonstrated a robust increase in
blood pressure in response to AngII (average change of 46.4 mmHg; p = 0.000392 via paired t-
test), and this response was absent in SS-AT1KO rats (average change of 0.82 mmHg; p = 0.56
via paired t-test).
AT1RA mutation does not alter expression of the Mas receptor or AT1RB
To determine whether altered receptor expression could account for the observed phenotypes,
we examined receptor expression in SS-AT1WT and SS-AT1KO cells. No difference in Mas1
expression was detected between SS-AT1WT and SS-AT1KO cells, suggesting that altered lev-
els of Mas1 do not account for phenotypic changes observed in this study (Fig 2C; p = 0.211
via 2-tailed t-test). Western blot confirmed the presence of Mas1 protein in both SS-AT1KO
and SS-AT1WT endothelial cells (Fig 2D; complete blot found in S1 raw images). No differ-
ences were detected in Mas1 protein expression between the two groups (Fig 2E; p = 0.44 via
2-tailed t-test).
Because rats express two forms of AT1R, we examined whether expression of AT1RB was
detectable in either SS-AT1WT or SS-AT1KO endothelial cells. Consistent with previous stud-
ies suggesting little to no expression of AT1RB in microvasculature[19], AT1RB was undetect-
able in both cell types. Note that expression of AT1RA is detectable but decreased (p = 0.00283
Fig 1. Validation of the AT1RA-specific knockout. (A) ZFNs specifically targeting the AT1RA (Agtr1a) gene were
designed in a region of exon 3 where specific sequence differences (underlined) would prevent ZFN binding and
mutagenesis of AT1RB (Agtr1b). The ZFN target is in bold and the specific monomer binding sites are underlined. A
frame-shifting 2-bp deletion results in the formation of an AccI restriction endonuclease site specifically in the AT1RA
mutant (boxed). (B) The frameshift results in an predicted early truncation of the nascent AT1RA peptide containing
87 normal amino acids and harboring only the first two of seven transmembrane domains, followed by 13 nonsense
amino acids. (C) PCR on cDNA reveals the expected amplification of AT1RA and AT1RB mRNAs with an expected
product of 171-bp (expected 169-bp for the AT1RA mutant). AccI restriction endonuclease specific cleavage of the
169-bp mutant AT1RA transcript into two fragments of 125 and 44-bp in AT1RA mutant rats (SS-AT1KO), but not
control SS animals (SS-AT1WT).
https://doi.org/10.1371/journal.pone.0232067.g001
PLOS ONE Mas1 and AT1R interaction in Ang-(1-7) signaling
PLOS ONE | https://doi.org/10.1371/journal.pone.0232067 April 23, 2020 9 / 23
PLOS ONE Mas1 and AT1R interaction in Ang-(1-7) signaling
PLOS ONE | https://doi.org/10.1371/journal.pone.0232067 April 23, 2020 10 / 23
via 2-tailed t-test), consistent with production and degradation of degenerate AT1RA
transcript.
AT1RA mutation abolishes the proangiogenic effects of Ang-(1–7) in vivo
We have previously shown that 7 days of muscle contraction induced by electrical stimulation
of the hind limb in vivo (ESTIM) produces a robust angiogenic response that is depressed in
the SS rat [1,17] and that chronic low-dose Ang-(1–7) infusion restores the angiogenic
response in these animals[1]. To determine whether AT1RA was necessary for this effect, we
performed ESTIM in SS-AT1WT and SS-AT1KO rats receiving low-dose Ang-(1–7) infusion
(Fig 3). ESTIM in combination with vehicle treatment (without low-dose Ang-(1–7)) did not
produce a significant increase in hind limb vessel density in either group (WT p = 0.1319; KO
p = 0.3803). Ang-(1–7) enhanced the effects of electrical stimulation in the SS-AT1WT group
(p = 0.0053) but had no effect in SS-AT1KO animals (p = 0.2582), suggesting that the AT1RA
is necessary for the effects of Ang-(1–7) on angiogenesis in response to electrical stimulation.
Note that in our previous work, competitive antagonism at AT1RA with losartan did not affect
the ability of Ang-(1–7) to enhance angiogenesis[3]. This suggests that the observed phenotype
is independent of ligand binding to the AT1R.
AT1RA mutation impairs the ability of Ang-(1–7) to enhance endothelial
cell tube formation in vitro
We have previously shown that Ang-(1–7) enhances the angiogenic capability of endothelial
cells in vitro [3]. To determine whether AT1RA contributes to this effect, tube formation in
SS-AT1WT cells and in SS-AT1KO cells was evaluated for 48 hours in the presence or absence
of Ang-(1–7), the Mas1 antagonist A779, the AT1R antagonist Losartan, and VEGF, a positive
control (Fig 4). Ang-(1–7) stimulated a significant increase in tube formation at both 24 hours
and 48 hours in SS-AT1WT cells but not in SS-AT1KO cells. This effect was attenuated by
antagonism of Mas1 but not affected by antagonism of AT1R. Both cell types demonstrated
increased tube formation in response to VEGF, demonstrating that SS-AT1KO endothelial
cells are able to respond to proangiogenic stimuli other than Ang-(1–7).
AT1RA mutation alters the transcriptional response to Ang-(1–7) in
endothelial cells
We previously observed that Ang-(1–7) treatment resulted in increased expression of proan-
giogenic transcripts in SS endothelial cells[3]. We compared the expression profile of angio-
genic transcripts in Ang-(1–7) and vehicle treated SS-AT1WT and SS-AT1KO endothelial
cells via qPCR. The trend in the overall dataset is for an Ang-(1–7) induced increase in expres-
sion in angiogenesis related transcripts in SS-AT1WT cells but not SS-AT1KO cells (Fig 5; R2
Fig 2. Physiological validation of AT1RA knockout model. Angiotensin II bolus (0.32ug/kg i.v.) causes an acute
increase in blood pressure in SS-AT1WT but not SS-AT1KO rats. A. Representative acute blood pressure tracings. B.
Baseline and peak blood pressure from all rats measured. Dashed lines represent individual animals while solid line
represents mean +/- standard deviation (� p< 0.05 vs baseline via paired t-test). C. Expression of AT1RA, AT1RB and
Mas1 was assessed in SS-AT1WT and SS-AT1KO endothelial cells. AT1RA expression was decreased in SS-AT1KO
cells, consistent with increased turnover of degenerate transcripts (� p< 0.05 vs SS-AT1WT via Students t-test; ^ not
detected). AT1RB was not detected in either group, and Mas1 expression was not altered by mutation of AT1RA.
Hypoxanthine-guanine phosphoribosyltransferatse 1 (HPRT1) was used as the control for dCT calculation. SS adrenal
gland, a tissue known to express all three receptors, was used as a positive control. D. Western blot for Mas1. Mas1 was
present in both SS-AT1WT and SS-AT1KO endothelial cells; each lane contains protein from a separately cultured
plate of endothelial cells. E. Relative quantification of Mas1 in SS-AT1WT and SS-AT1KO EC lysates. No difference
was detected between these groups (n = 4; p = 0.442 via Students t-test).
https://doi.org/10.1371/journal.pone.0232067.g002
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= 9.2x10-5). Hypothesis testing via Deming regression showed that the slope representing the
relationship between SS-AT1WT and SS-AT1KO values was different from 1 (p < 0.0005) but
not different from 0 (p = 0.87).
Of 84 genes that were tested, 19 were excluded from our analysis due to amplification fail-
ure in 2 or more biological replicates within a single experimental group. These data are avail-
able in S5 Table. Ang-(1–7) treatment resulted in significant changes in the expression of 9
genes in SS-AT1WT cells but only 1 transcript in SS-AT1KO cells (Table 1). After correction
for multiple comparisons via modified Hochberg step-up procedure[31] with FDR set at 0.05,
Fig 3. Angiotensin-(1–7) enhances angiogenesis in SS-AT1WT but not SS-AT1KO rats. Rats underwent electrical
stimulation of one hind-limb for 7 days while infused with saline or 3ng/kg/min Ang-(1–7) via jugular catheter. A.
Plots of vessel density of stimulated and unstimulated hind limbs. Dashed lines represent individual rats while bolded
bars represent mean +/- standard deviation (� p< 0.05 vs unstimulated limb via paired t-test). B-C. Representative
vessel density images from each group. ^ Units are vessel-grid intersections per microscope field as described in the
methods.
https://doi.org/10.1371/journal.pone.0232067.g003
Fig 4. Angiotensin-(1–7) enhances endothelial cell tube formation in SS-AT1WT but not SS-AT1KO endothelial
cells. Endothelial cells spontaneously form tube-like structures when cultured in a basement-membrane like matrix. A.
SS-AT1WT endothelial cell tube length at 24 hours. B. SS-AT1KO endothelial cell tube length at 24 hours. C.
SS-AT1WT endothelial cell tube length at 48 hours. D. SS-AT1KO endothelial cell tube length at 48 hours. Bars
represent mean +/- standard deviation (� p< 0.05 vs none via 1-way ANOVA with Dunnett’s Method for multiple
comparisons). None = control, Ang1-7 = angiotensin-(1–7), A779 = Mas1 antagonist, Losartan = AT1 antagonist,
VEGF = vascular endothelial growth factor.
https://doi.org/10.1371/journal.pone.0232067.g004
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significant changes were detected in the expression of 5 genes in SS-AT1WT cells but only 1
transcript in SS-AT1KO cells.
Fig 5. AT1RA contributes to the transcriptional response to Ang-(1–7). Levels of mRNA associated with
angiogenesis pathways increased upon stimulation with Ang-(1–7) in Dahl salt-sensitive endothelial cells but not AT1a
knockout cells. Values represent fold change in expression as detected via qPCR, with SS-AT1WT value on the x-axis
and SS-AT1KO values on the y-axis (R2 = 9.2x10-5). Hypothesis testing via Deming regression showed that the slope
representing the relationship between SS-AT1WT and SS-AT1KO values was different from 1 (p< 0.0005) but not
different from 0 (p = 0.87).
https://doi.org/10.1371/journal.pone.0232067.g005
Table 1. Analysis of an angiogenesis RT-PCR gene expression array following Ang-(1–7) stimulation of rat microvascular endothelial cells.









Akt1 AKT serine/threonine kinase
1
1.54 0.030 1.21 0.396 PDGF, cell survival, angiogenesis, insulin
signaling
Fgfr3 Fibroblast growth factor
receptor 3
1.89 0.006^ 1.36 0.016^ PI3K/AKT activation, angiogenesis, apoptosis
Il1b Interleukin-1 beta 2.03 0.034 2.32 0.080 NF-kappaB signaling, MAPK/ERK, JAK-STAT,
AKT, TLR signaling
Mmp2 72 kDa type IV collagenase 2.00 0.029 1.22 0.126 adhesion, angiogenesis, Tie2 signaling, immune
cell transmigration
Ptgs1 Prostaglandin G/H synthase
1
1.66 0.019^ 1.19 0.132 prostaglandin signaling
Ptk2 Focal adhesion kinase 1 1.73 0.032 1.15 0.063 migration, PI3K, AKT, MAPK/ERK, Rho GTPase
signaling
Tgfb3 Transforming growth factor
beta-3
2.13 0.003^ 1.15 0.331 p38-MAPK, angiogenesis, Wnt/Hedgehog/Notch
Tgfbr1 TGF-beta receptor type-1 2.09 0.000^ 1.29 0.093 angiogenesis, Wnt/Hedgehog/Notch, apoptosis,
AKT, NF-kappaB
Thbs1 Thrombospondin-1 2.12 0.003^ 1.13 0.065 TGF-beta, angiogenesis, adhesion, PI3K/AKT
Table includes all genes with significant fold change in gene expression in at least one strain (p�0.05; paired t-test within plate); biologic processes include but are not
limited to those above (N = 3).
�Indicates 100 nM Ang-(1–7) stimulated versus unstimulated endothelial cells.
^ Indicates that p-value remained significant after correction for multiple comparisons via modified Hochberg step-up procedure[31] with FDR set at 0.05.
https://doi.org/10.1371/journal.pone.0232067.t001
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AT1RA mutation alters the protein complex formed upon binding of Ang-
(1–7) to the Mas receptor
Previously, we identified components of the Ang-(1–7)/Mas1 signaling complex[3]. Using this
data as a baseline for analysis, we performed a new experiment using tandem mass spectrome-
try-based proteomics to identify molecules upregulated in, or unique to, the Ang-(1–7) acti-
vated Mas1 signaling complex in SS-AT1WT endothelial cells but not in SS-AT1KO cells.
Because AT1R is a component of the Ang-(1–7)/Mas1 signaling complex in SS-AT1WT cells
[3] and physiological and transcriptional responses to Ang-(1–7) are altered in SS-AT1KO
cells (Figs 3–5), we hypothesized that the Ang-(1–7)/Mas1 signaling complex would be altered
in SS-AT1KO cells.
The technique used here is cryolysis followed by co-immunoprecipitation as described in
our previous study [3] and in the reagent manufacturer’s user guide (Thermo Fisher 14321D).
Cryolysis stabilizes large protein complexes, facilitating their isolation together and promoting
minimal loss in the complex. This provides a deeper magnitude of identification into the pro-
tein binding complex compared to simple co-immunoprecipitation. Note that this means
identified proteins do not all bind directly to the target, in this case Mas1, but rather that they
are part of a complex of interacting proteins.
Table 2 shows the complete list of proteins that met our criteria as AT1R related compo-
nents of the Ang-(1–7)/Mas1 signaling complex: FDR < 5%, statistically significant difference
between treated and untreated experimental groups (normalized p-value < .05), at least a
2-fold enrichment in the Ang-(1–7) treated group, presence in greater than 50% of replicates
in at least one experimental group, at least 6 scans detected, and upregulation in the
SS-AT1WT comparison but not the SS-AT1KO comparison. Note that several of these pro-
teins are part of the previously described Ang-(1–7)/Mas1 signaling complex[3]. The proteo-
mic datasets can be found in supplemental materials (S3 Table and S4 Table).
Fig 6 shows a simplified version of the Ang-(1–7)/Mas signaling pathway previously
described [3]. Proteins and mRNA transcripts previously identified in the Mas signaling path-
way and associated with AT1RA based on the present study are denoted in color while other
previously identified components are represented in grey. Of note are the NOTCH family of
proteins and protein kinase D1, both of which were identified in the Ang-(1–7)/Mas1 signaling
complex previously and are related to known angiogenesis signaling pathways involving ERK,
p38-MAPK, and/or Akt[3].
This data may also be useful in developing hypotheses regarding potential AT1R indepen-
dent actions of Ang-(1–7) via Mas1. S2 Table shows proteins that may be related to AT1R
independent signaling downstream of the Ang-(1–7) complex. This table was formed by apply-
ing the following criteria: FDR< 5%, statistically significant difference between treated and
untreated experimental groups (normalized p-value< .05), at least a 2-fold enrichment in the
Ang-(1–7) treated group, presence in greater than 50% of replicates in at least one experimen-
tal group, at least scans detected, and upregulation in the SS-AT1KO comparison but not the
SS-AT1WT comparison. Of particular interest may be PAK4 (log2ratio = 4.09; p = 3.31x10-5),
which promotes cell survival [32,33], affects cell adhesion [34] and is implicated in the epithe-
lial-mesenchymal transition in cancer [35], and PA2G4 (log2ratio = 2.58; p = 0.046), a DNA
binding protein [36] which is implicated in both development [37] and a variety of cancers
[38,39].
Discussion
The current study provides both physiological and biochemical support for an interaction
between AT1R and Mas1 signal transduction. It has been previously hypothesized that AT1R
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and Mas1 heterodimerize[12]. However, the mechanism and functional effects of this potential
interaction are still being examined. Kostenis and colleagues showed that AT1R and Mas co-
localize using bioluminescence resonance energy transfer (BRET) and observed that expres-
sion of Mas decreased AngII signaling despite an increase in AngII binding capacity[12]. It has
been shown that Mas receptor knockout has little to no effect on the ability of AT1R to bind
AngII, suggesting that competitive binding of AngII to Mas is unlikely to account for the
decreased AngII signaling observed by Kostenis and colleagues[5]. Another study observed
rescue of function of a mutant AT1R by Mas1 expression, which altered the distribution of the
mutant AT1R within the cell[13]. These findings support the hypothesis that dimerization
occurs between AT1R and Mas1.
While the mechanism and conformation of AT1R and Mas1 interaction at the molecular
level must still be examined directly, the current results strongly suggest that interaction of
AT1RA and Mas1 is necessary for the transduction of signals downstream of Ang1-7/Mas1
binding in endothelial cells. Previously, AT1RA was identified in the immunoprecipitated
Ang1-7/Mas1 protein complex [3], suggesting physical proximity. This identification only
occurred when Mas1 was bound to its ligand, Ang1-7, suggesting a functional interaction. Sev-
eral downstream proteins identified in the Ang1-7/Mas1 protein complex are known media-
tors of AT1RA signaling, consistent with a transactivation-like signaling event that requires
interaction between AT1RA and Mas1 to achieve complete signal transduction. In the present
study, absence of AT1RA abolishes the physiological effect of Ang1-7 both in vivo and in vitro
(Figs 3 and 4) as well as the transcriptional response to Ang-(1–7), supporting the hypothesis
that proangiogenic Ang1-7/Mas1 signaling is altered in the absence of AT1RA (Table 1; Fig 5).
Table 2. Ang-(1–7) stimulated MAS1 receptor immuno-precipitation divergent ‘top proteomic hits’.
Accession
Number
Annotated Protein NormLog2Ratio� norm. p-
value�
Notable signaling involvement
Q8BIZ0 Protocadherin-20 (Pcdh20) Unique 3.63E-08 Calcium-dependent cell-adhesion
Q63532 Cornifin-A (SPR1A) Unique 1.42E-07 Membrane cross-linking
Q62101 Serine/threonine-protein kinase D1
(PRKD1)
Unique 6.93E-05 PKC (+), DAG (+), ERK1/2 (+), IKK/NFkB (+), p38MAPK (+),
AKT (+) and EGF (-) Signaling
Q80UN1 BTB/POZ domain-containing protein
KCTD9
Unique 2.38E-03 Protein ubiquitination
Q9QYR6 Microtubule-associated protein 1A (Map1a) Unique 4.90E-03 Structural protein
Q99466^ Neurogenic locus notch homolog protein
(NOTCH) family^
Unique 2.16E-02 Cell Survival Signaling (+), angiogenesis
P04095 Proliferin-1 precursor (Mitogen-regulated
protein 1)
4.36 2.39E-06 Growth factor and/or angiogenesis factor
O35625 Axis inhibition protein 1 (Axin-1) 4.15 1.63E-05 Wnt-signaling modification; JNK signaling
Q7TPH6 E3 ubiquitin-protein ligase MYCBP2 3.60 1.80E-06 Ubiquitination; transcriptional regulator of MYC
Q9JK88 Serpin I2 3.60 7.35E-04 Endopeptidase inhibitor
Q01887 Tyrosine-protein kinase RYK 3.27 5.83E-07 Wnt coreceptor
Q9JHZ9 Sodium-coupled neutral amino acid
transporter 3 (Slc38a3)
1.93 8.21E-06 Sodium-dependent aa/proton transporter
Q6P542 ATP-binding cassette sub-family F member
1 (Abcf1)
1.95 5.80E-13 mRNA translation initiation; not ribosome biogenesis
P48744 Norrin precursor 1.60 1.61E-05 Wnt signaling; retinal vascularization
All proteins indicated passed all stringent filters indicated in the Methods; full protein lists can be found in S3 Table and S4 Table.
�Mas1 IP: 100 nM Ang-(1–7) stimulated SS EC versus unstimulated SS EC (Per condition: N = 3; 6 total runs)
^Peptides mapped to multiple members of the NOTCH family; accession for NOTCH4 was used based on previous findings [3].
https://doi.org/10.1371/journal.pone.0232067.t002
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In further support of this hypothesis, the composition of the Ang1-7/Mas1 protein complex is
altered in the absence of AT1RA (Table 2).
Changes in the Ang-(1–7)/Mas signaling complex in the absence of intact AT1R suggest
avenues for further study. Several candidates are identified in Fig 6. These potential AT1R-
dependent members of the Mas1 signaling complex have previously established roles in angio-
genesis, as outlined below.
Protein kinase D1 (PRKD1) is implicated here and is known to affect angiogenesis in sev-
eral ways. In human umbilical vein endothelial cells, PRKD1 is required for VEGF-induced
angiogenesis mediated by histone deacetylase 5 (HDAC5) [40]. Furthermore, knockdown of
PRKD1 inhibits physiological angiogenesis and abolishes tumor angiogenesis in zebrafish
[41]. Akt, a known regulator of angiogenesis, is in turn regulated by PRKD1 downstream of G
protein-coupled receptors [42,43]. AngII is known to activate PRKD1[44], which has been
shown to induce phosphorylation of ERK and increase the duration of ERK activation[45]. In
the context of our studies, it is possible that Ang-(1–7)/Mas1 regulates Akt, ERK and/or
HDAC5 via AT1R activation of PRKD1.
Our data implicate the Notch family of signaling components as a proangiogenic signaling
mechanism in endothelial cells downstream of the Mas1/AT1RA complex. Notch proteins are
known to play a complex regulatory role in the formation of new blood vessels. Functions of
Notch signaling include cell type specification, proliferation, and vessel stability, among others
[46]. For example, activated Notch4 inhibits human microvascular endothelial cell sprouting
in response to FGF-2 and VEGF [47], and constitutively active Notch4 has been shown to
inhibit endothelial cell apoptosis [48]. Previous studies in our laboratory identified Notch4 as a
member of the Ang-(1–7)/Mas signaling complex in endothelial cells [3] and Notch3 as a
potential mediator of endothelial progenitor cell (EPC) dysfunction [49]. EPCs are bone-
Fig 6. Diagram of suggested AT1A dependent components of the Ang1-7/Mas signaling complex. Unless otherwise
noted, molecules represented here were previously identified as components of the Ang-(1–7)/Mas1 signaling
complex. Colored molecules represent AT1RA dependent components detected in the current study via mass
spectrometry-based proteomics (blue label) and/or qPCR (red label). �Peptides mapped to NOTCH were not unique
to specific NOTCH family members. ^RYK was not detected in our previous study but was included here due to
known links to angiogenesis.
https://doi.org/10.1371/journal.pone.0232067.g006
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marrow derived stem-cells that contribute to therapeutic angiogenesis in animal models [50].
The therapeutic efficacy of EPCs in the SS rat is compromised, and our previous study suggests
that this dysfunction is linked to altered methylation of Notch3 that leads to suppression of
Notch3 expression [49].
RYK, a receptor for Wnt5a, was also suggested to be an AT1R dependent member of the
Ang-(1–7)/Mas signaling complex. Wnt5a signaling is known to enhance the proliferation,
survival, and migration of endothelial cells[51,52]. In addition, expression of transforming
growth factor beta-3 (Tgfb3) and TGF-beta receptor type-1 (Tgfbr1) transcripts—both of
which are involved in crosstalk with Wnt signaling[53,54]—was upregulated after Ang-(1–7)
treatment in SS-AT1WT but not SS-AT1KO endothelial cells. Thus, despite lack of a more
direct link between AT1R, Mas1, and RYK, Wnt signaling via RYK represents another strong
candidate for further study.
The present study also identified several other well-known mediators of proangiogenic sig-
naling that are responsive to Ang-(1–7) as potentially AT1RA dependent, by either transcrip-
tional changes or implied pathway identification. It is important to note that altered mRNA
levels are likely to be due to altered transcription, trafficking, or degradation, all of which are
downstream effects of signaling per se. Thus, molecules downstream of signaling components
identified via mass spectrometry, such as Akt, could contribute to signaling while those identi-
fied only by qPCR, such as Fgfr3 and Mmp2, may represent effects of signaling rather than
mediators of signal transduction.
An important limitation of this study is the assumption that Ang-(1–7) does not exert its
proangiogenic effects via binding to AT1R. This assumption is based upon our previous find-
ing that the proangiogenic effects of Ang-(1–7) are blocked by the Mas1 antagonist A779 but
not by the AT1R antagonist losartan [3]. It is possible that yet to be understood complexity
will invalidate this assumption. For instance, an altered conformation of heterodimerized
AT1R could allow Ang-(1–7) to bind AT1R despite the presence of losartan. However, note
that the convergent, proangiogenic effects of AngII in our model were attenuated in the pres-
ence of losartan [3]. Unless AngII and Ang-(1–7) act via separate sets of AT1R, binding of
AT1R by Ang-(1–7) in the presence of losartan is an unlikely mechanism for these losartan-
independent proangiogenic effects. Given that the strongest evidence for Ang-(1–7) binding
AT1R is displacement of AngII [55,56], we do not believe that binding of Ang-(1–7) to a sepa-
rate set of AT1R that are unaffected by losartan is responsible for the proangiogenic effects
observed in our model. Note that we do not discount AT1R binding as a mechanism for other
effects mediated by Ang-(1–7). In fact, this possibility is of ongoing interest in the field. For
instance, there is evidence that Ang-(1–7) can act as a biased ligand in cells expressing AT1R
but not Mas1 [57]. There is also recent work suggesting that Ang-(1–7) does not interact
directly with Mas1 [58]. This is in conflict with work demonstrating that Ang-(1–7) exerts
effects via Mas1 [5], including in cells expressing Mas1 but not AT1R [59] and work that dem-
onstrates Ang-(1–7) induced Mas1 internalization [60]. Given the ever-growing complexity of
the renin-angiotensin system [61,62], including transactivation of Mas1 downstream of AngII
[63], it seems unlikely that the effects of Ang-(1–7) are mediated via a single receptor. It will be
important to reassess this work and other work in the field as our understanding of this com-
plexity grows.
These data may be useful in developing hypotheses regarding AT1R independent Mas1 sig-
naling. Given that the remainder of the data presented here examines only AT1R dependent
effects of Ang-(1–7)/Mas1 signaling, the conclusions that can be drawn are limited. With this
limitation in mind, several proteins of interest were identified as potential AT1R independent
mediators of Ang-(1–7)/Mas1 signaling (S2 Table). Mas1 was first described as an oncogene
[64] and continues to be of interest in cancer [65,66]. Therefore, PAX4 and PA2G4, both of
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which are implicated in the development of cancer [35,38,39] and were identified here as a
potential mediators of AT1R independent Ang-(1–7)/Mas1 signaling, represent ideal candi-
dates for further study. In particular, PAK4, which regulates cell adhesion [34] and apoptosis
[32], is of interest in this context given the known effects on cell growth and/or metastasis by
Ang-(1–7)/Mas1 in nasopharyngeal carcinoma [67], prostate cancer [68,69], breast cancer
[70], and other cancers [71].
This study, combined with our previous work showing the presence of AT1R in the acti-
vated Ang-(1–7)/Mas signaling complex, suggests that physical interaction of Mas1 and AT1R
is important for signal transduction. Future work will seek to identify AT1R/Mas1 conforma-
tions consistent with attributes consistent with heterodimerization or oligomerization. Under-
standing of this protein complex at a structural level will allow the creation of higher
resolution models to examine the effect of disrupted dimerization in the presence of otherwise
functional receptors and enable further investigation of genetic differences that could lead to
increased cardiovascular risk via disruption of AT1R/Mas1 binding.
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